% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Stamelou:137116,
      author       = {Stamelou, Maria and Höglinger, Günter},
      title        = {{A}typical parkinsonism: an update.},
      journal      = {Current opinion in neurology},
      volume       = {26},
      number       = {4},
      issn         = {1350-7540},
      address      = {[S.l.]},
      publisher    = {Ovid},
      reportid     = {DZNE-2020-03438},
      pages        = {401-405},
      year         = {2013},
      abstract     = {This update discusses novel aspects on genetics, diagnosis,
                      and treatments of atypical parkinsonism published over the
                      past 2 years.A genome-wide association study identified new
                      genetic risk factors for progressive supranuclear palsy and
                      new genetic conditions presenting with atypical parkinsonism
                      have been described. The clinical criteria for diagnosis of
                      corticobasal degeneration have been revised, and for
                      progressive supranuclear palsy are under revision. Novel
                      molecular techniques to identify possible biomarkers, as in
                      other neurodegenerative disorders, have started being
                      studied on atypical parkinsonian conditions, and although
                      preliminary results seem promising, further studies are
                      urgently warranted. Therapeutic trials based on
                      disease-specific targets have shown no clinical
                      improvement.The knowledge obtained recently on atypical
                      parkinsonian conditions points out the major deficits in
                      this field. With the expanding phenotypical spectrum of
                      atypical parkinsonian conditions, the early identification
                      of patients has become difficult. The inability of
                      conventional methods to identify these disorders earlier and
                      better than clinicians, and the recent failure of promising
                      therapeutic compounds, highlight the fact that the lack of
                      biomarkers is probably the greatest limitation for
                      developing treatments for these disorders. Thus, current and
                      future research in this direction will be crucial.},
      subtyp        = {Review Article},
      keywords     = {Diagnosis, Differential / Genome-Wide Association Study /
                      Humans / Neuroimaging / Parkinsonian Disorders: diagnosis /
                      Parkinsonian Disorders: genetics / Parkinsonian Disorders:
                      pathology / Risk Factors / Severity of Illness Index /
                      Supranuclear Palsy, Progressive: diagnosis},
      cin          = {AG Höglinger 1},
      ddc          = {610},
      cid          = {I:(DE-2719)1110002},
      pnm          = {344 - Clinical and Health Care Research (POF3-344)},
      pid          = {G:(DE-HGF)POF3-344},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:23812308},
      pmc          = {pmc:PMC4196800},
      doi          = {10.1097/WCO.0b013e3283632da6},
      url          = {https://pub.dzne.de/record/137116},
}